Tyra Biosciences, Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
TYRA BIOSCIENCES, INC.
/s/ Todd Harris, Ph.D.
Todd Harris, Ph.D.President, Chief Executive Officer, and Director
Date: March 27, 2025
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Todd Harris, Ph.D. | President, Chief Executive Officer and Director | March 27, 2025 |
| Todd Harris, Ph.D. | (principal executive officer) | |
| /s/ Alan Fuhrman | Chief Financial Officer | March 27, 2025 |
| Alan Fuhrman | (principal financial and accounting officer) | |
| /s/ Adele M. Gulfo | Director | March 27, 2025 |
| Adele M. Gulfo | ||
| /s/ Gilla Kaplan, Ph.D. | Director | March 27, 2025 |
| Gilla Kaplan, Ph.D. | ||
| /s/ Melissa McCracken, Ph.D. | Director | March 27, 2025 |
| Melissa McCracken, Ph.D. | ||
| /s/ Susan Moran, M.D., M.S.C.E. | Director | March 27, 2025 |
| Susan Moran, M.D., M.S.C.E. | ||
| /s/ Robert More | Director | March 27, 2025 |
| Robert More | ||
| /s/ S. Michael Rothenberg, M.D., Ph.D. | Director | March 27, 2025 |
| S. Michael Rothenberg, M.D., Ph.D. | ||
| /s/ Jake Simson, Ph.D | Director | March 27, 2025 |
| Jake Simson, Ph.D. | ||
| /s/ Rehan Verjee | Director | March 27, 2025 |
| Rehan Verjee | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.